Hodgkin's lymphoma: the pathologist's viewpoint. Issue 3 (1st March 2002)

• Record Type: Journal Article
• Authors: Pileri, S A; Ascani, S; Leoncini, L; Sabattini, E; Zinzani, P L; Piccaluga, P P; Pileri, A; Giunti, M; Falini, B; Bolis, G B; Stein, H
• Is Part Of: Journal of clinical pathology. Volume 55:Issue 3(2002)
• Page Start: 162
• Page End: 176
• Publication Date: 2002-03-01
• Subjects: Hodgkin's lymphoma -- differential diagnosis -- subtypes -- Epstein-Barr virus; ALCL, anaplastic large cell lymphoma -- ALCL-HL, ALCL Hodgkin-like type -- BNLI, British national lymphoma investigation -- CHL, common Hodgkin's lymphoma -- DLBCL, diffuse large B cell lymphoma -- EBER, Epstein-Barr virus early RNA -- EBV, Epstein-Barr virus -- EMA, epithelial membrane antigen -- FDC, follicular dendritic cell -- FL, follicular lymphoma -- HC, Hodgkin's cell -- HCRBCL, histiocyte rich large B cell lymphoma -- HD, Hodgkin's disease -- HIV, human immunodeficiency virus -- HL, Hodgkin's lymphoma -- H&RS, Hodgkin's and Reed-Sternberg -- IL, interleukin -- LD-CHL, lymphocyte depletion CHL -- L/H, lymphocytic/histiocytic -- LL, Lennert's lymphoma -- LMP, latent membrane protein -- LP-HL, lymphocyte predominant HL -- LR-CHL, lymphocyte rich CHL -- MC-CHL, mixed cellularity CHL -- NHL, non-Hodgkin's lymphoma -- NS-CHL, nodular sclerosis CHL -- PCNA, proliferating cell nuclear antigen -- PCR, polymerase chain reaction -- PMLBCL, primary mediastinal large B cell lymphoma -- PTGC, progressively transformed germinal centre -- REAL, revised European–American -- RS, Reed-Sternberg -- TCR, T cell receptor -- TCRBCL, T cell rich B cell lymphoma -- TNF, tumour necrosis factor -- WHO, World Health Organisation; Pathology -- Periodicals; Pathology, Molecular -- Periodicals; 616.0705
• Languages: English
• ISSNs: 0021-9746

Abstract

Abstract : Despite its well known histological and clinical features, Hodgkin's lymphoma (HL) has recently been the object of intense research activity, leading to a better understanding of its phenotype, molecular characteristics, histogenesis, and possible mechanisms of lymphomagenesis. There is complete consensus on the B cell derivation of the tumour in most cases, and on the relevance of Epstein-Barr virus infection and defective cytokinesis in at least a proportion of patients. The REAL/WHO classification recognises a basic distinction between lymphocyte predominance HL (LP-HL) and classic HL (CHL), reflecting the differences in clinical presentation and behaviour, morphology, phenotype, and molecular features. CHL has been classified into four subtypes: lymphocyte rich, nodular sclerosing, with mixed cellularity, and lymphocyte depleted. The borders between CHL and anaplastic large cell lymphoma have become sharper, whereas those between LP-HL and T cell rich B cell lymphoma remain ill defined. Treatments adjusted to the pathobiological characteristics of the tumour in at risk patients have been proposed and are on the way to being applied.